Lixte Biotechnology Free Cash Flow Over Time
| LIXT Stock | USD 1.91 0.04 2.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lixte Biotechnology Performance and Lixte Biotechnology Correlation. Lixte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Return On Assets (0.87) | Return On Equity (1.63) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Analysis
Compare Lixte Biotechnology and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Free Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (7.3 M) | (15.1 M) | (16.8 M) | (12.7 M) | (13.4 M) |
| VRAX | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (744.6 K) | (590.2 K) | (809.1 K) | (4.4 M) | (7.4 M) | (7 M) |
| QNRX | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6.5 M) | (1.4 M) | (1.5 M) | (6.3 M) | (8.7 M) | (7.9 M) | (8.3 M) |
| INDP | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (3.3 M) | (11.3 M) | (13.3 M) | (13.4 M) | (14.1 M) |
| KTTA | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (38.7 K) | (3.2 M) | (16.7 M) | (13.5 M) | (12.8 M) |
| BDRX | (3.5 M) | (3.5 M) | (3.5 M) | (4.5 M) | (6.5 M) | (13.3 M) | (14.4 M) | (13.7 M) | (13.7 M) | (6.8 M) | (9.5 M) | (6.3 M) | (7.1 M) | (7.1 M) | (7.4 M) |
| PMVP | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (22.2 M) | (32.9 M) | (47.9 M) | (71.7 M) | (56.6 M) | (59.4 M) |
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (3.1 M) | (19.9 M) | (52.3 M) | (82.4 M) | (83.7 M) | (79.5 M) |
| SRRK | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (22.1 M) | 23.1 M | (66.2 M) | (64.4 M) | (132 M) | (133.8 M) | (145.3 M) | (138 M) |
| PASG | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (41.6 M) | (82.2 M) | (152.5 M) | (123.5 M) | (78.4 M) | (82.3 M) |
Lixte Biotechnology and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Free Cash Flow description
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.My Equities
My Current Equities and Potential Positions
| Lixte Biotechnology Holdings | LIXT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.91
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.